Sarah Blagden, Hani Gabra, Imperial College London, Ovarian Cancer Action Research Center ... whilst definitely the gold standard for serous and endometrioid histology, may not be the most ...

Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently more than 300,000 new cases and 200,000 deaths annually, according to data ...

Some risk factors for epithelial ovarian cancer are modifiable, according to a study published online Jan. 6 in the ...

High-grade serous ovarian cancer (HGSOC) is the most common type of epithelial ovarian cancer and is often diagnosed at an advanced stage, making treatment a challenge and the need for earlier ...

Long-term survival in women with epithelial ovarian cancer (EOC) has not increased ... outcomes and increasing CD8+ TILs in high-grade serous, endometrioid, and mucinous ovarian cancers.

Ovarian cancer continues to pose a significant challenge in the medical field, remaining one of the leading causes of death ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

Patients with stage III epithelial ovarian cancer (EOC ... treatment for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).

High use of neoadjuvant chemotherapy in patients with advanced ovarian cancer has also been shown to lead to greater improvements in short-term mortality and equivalent gains in median overall ...